Comparing Renin and Lactic Acid Levels to Predict Mortality in Critically Ill Patients
Use of Renin Versus Lactic Acid as Tissue Perfusion Biomarkers for Mortality Prediction in Hypotensive Critically Ill Patients
This study is testing if measuring renin and lactic acid levels can help predict survival in critically ill patients who are on medication to support their blood pressure.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 84 (estimated) |
| Ages | 21 Years to 60 Years |
| Sex | All |
| Sponsor | Al-Azhar University Academic / other |
| Locations | 2 sites (Madīnat An Naşr, Cairo and 1 other locations) |
| Trial ID | NCT05810415 on ClinicalTrials.gov |
What this trial studies
This observational study aims to evaluate the effectiveness of serum renin levels compared to whole blood lactate concentrations as biomarkers for predicting mortality in hypotensive critically ill patients. Patients aged 21-60 who are receiving vasopressors and are expected to stay in the ICU for more than 24 hours will have their renin and lactate levels measured at enrollment and at 24, 48, and 72 hours. The study will track patient characteristics, ICU admission reasons, length of stay, and mortality outcomes to determine the prognostic value of these biomarkers. Data will be collected until the patient either dies or is discharged from the ICU.
Who should consider this trial
Good fit: Ideal candidates are critically ill patients aged 21-60 who are on vasopressors and expected to remain in the ICU for over 24 hours.
Not a fit: Patients on renal replacement therapy or those receiving beta-blockers may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve mortality prediction in critically ill patients, leading to better-targeted interventions.
How similar studies have performed: While the use of lactate as a prognostic marker is established, the evaluation of renin as a predictive biomarker in this context is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients aged 21-60 years old 2. Those receiving vasopressors for greater than or equal to 6 hours to maintain a mean arterial pressure (MAP) ≥65 mm Hg. 3. Anticipated stay \>24 hours. Exclusion Criteria: 1. Patients or families refusing to participate in the study. 2. Patients on renal replacement therapy. 3. Patients receiving betablockers
Where this trial is running
Madīnat An Naşr, Cairo and 1 other locations
- Azhar University — Madīnat An Naşr, Cairo, Egypt (Recruiting)
- Azhar unversity — Cairo, Egypt (Completed)
Study contacts
- Study coordinator: Abd El-Wahab AS Mohammed, AP
- Email: abdelwahabsaleh7020@gmail.com
- Phone: +2(045)33343945
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.